Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights
The liver is pivotal in protein synthesis, glucose and lipid metabolism, and detoxification. However, the liver is susceptible to both acute and chronic disorders, with chronic conditions being fatal. Chronic liver diseases (CLDs), such as liver fibrosis, which usually represents the early manifesta...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-06-01
|
| Series: | Liver Research |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2542568425000273 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850207812881219584 |
|---|---|
| author | Sathiyamoorthy Padmanaban Ji-Won Baek Sai Sahithya Chamarthy Saipriya Chandrasekaran Antony V Samrot Vijayakumar Gosu In-Kyu Park Kamalakannan Radhakrishnan Don-Kyu Kim |
| author_facet | Sathiyamoorthy Padmanaban Ji-Won Baek Sai Sahithya Chamarthy Saipriya Chandrasekaran Antony V Samrot Vijayakumar Gosu In-Kyu Park Kamalakannan Radhakrishnan Don-Kyu Kim |
| author_sort | Sathiyamoorthy Padmanaban |
| collection | DOAJ |
| description | The liver is pivotal in protein synthesis, glucose and lipid metabolism, and detoxification. However, the liver is susceptible to both acute and chronic disorders, with chronic conditions being fatal. Chronic liver diseases (CLDs), such as liver fibrosis, which usually represents the early manifestation of cirrhosis, primarily result from hepatitis B and C viruses infections, metabolic disorders, alcohol abuse, immune-mediated attacks, and cholestatic injury. The progression of liver fibrosis contributes to the development of cirrhosis, which can further lead to hepatocellular carcinoma, portal hypertension, hepatic decompensation, and hepatic encephalopathy. The extracellular matrix deposition over time leading the hepatocyte necrosis (cirrhosis) is the main structural feature of CLDs and may cause hepatic failure. Certain conditions, such as hepatitis and autoimmune diseases, may promote the rapid deterioration of liver function. Acute and chronic liver failure causes may vary, with early referral for liver transplantation improving the chance of recovery. The healthcare system need improvements to manage patients with non-alcoholic fatty liver disease and alcoholic fatty liver disease, as they have the potential to progress to cirrhosis. Both conditions involve the release of reactive oxygen species and damage-associated molecular patterns from cytokines, hepatic stellate cells, and hepatocyte autophagy, leading to prolonged inflammation. While various medications target fibrosis and liver damage, nanoparticle-based drug delivery systems offer additional promise by promoting faster liver regeneration. This review provides a comprehensive overview of the potential of nanoparticle systems as a future therapeutic approach for treating liver disorders. |
| format | Article |
| id | doaj-art-ad1d57a4a32f4eee8b4d1d30b51bb6f7 |
| institution | OA Journals |
| issn | 2542-5684 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Liver Research |
| spelling | doaj-art-ad1d57a4a32f4eee8b4d1d30b51bb6f72025-08-20T02:10:24ZengKeAi Communications Co., Ltd.Liver Research2542-56842025-06-019210411710.1016/j.livres.2025.04.002Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insightsSathiyamoorthy Padmanaban0Ji-Won Baek1Sai Sahithya Chamarthy2Saipriya Chandrasekaran3Antony V Samrot4Vijayakumar Gosu5In-Kyu Park6Kamalakannan Radhakrishnan7Don-Kyu Kim8Department of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju, Republic of KoreaHost-directed Antiviral Research Center, Department of Integrative Food, Bioscience and Biotechnology (BK21 FOUR), Chonnam National University, Gwangju, Republic of KoreaDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Sanford Consortium for Regenerative Medicine, University of California San Diego (UCSD), San Diego, CA, USADepartment of Neuroscience, University of California San Diego (UCSD), San Diego, CA, USADepartment of Microbiology, Faculty of Medicine, Manipal University College Malaysia, Melaka, MalaysiaDepartment of Animal Biotechnology, Jeonbuk National University, Jeonju, Republic of KoreaDepartment of Biomedical Sciences and BioMedical Sciences Graduate Program (BMSGP), Chonnam National University Medical School, Gwangju, Republic of Korea; Corresponding author.Host-directed Antiviral Research Center, School of Biological Sciences and Technology, Chonnam National University, Gwangju, Republic of Korea; Corresponding author.Host-directed Antiviral Research Center, Department of Integrative Food, Bioscience and Biotechnology (BK21 FOUR), Chonnam National University, Gwangju, Republic of Korea; Corresponding author.The liver is pivotal in protein synthesis, glucose and lipid metabolism, and detoxification. However, the liver is susceptible to both acute and chronic disorders, with chronic conditions being fatal. Chronic liver diseases (CLDs), such as liver fibrosis, which usually represents the early manifestation of cirrhosis, primarily result from hepatitis B and C viruses infections, metabolic disorders, alcohol abuse, immune-mediated attacks, and cholestatic injury. The progression of liver fibrosis contributes to the development of cirrhosis, which can further lead to hepatocellular carcinoma, portal hypertension, hepatic decompensation, and hepatic encephalopathy. The extracellular matrix deposition over time leading the hepatocyte necrosis (cirrhosis) is the main structural feature of CLDs and may cause hepatic failure. Certain conditions, such as hepatitis and autoimmune diseases, may promote the rapid deterioration of liver function. Acute and chronic liver failure causes may vary, with early referral for liver transplantation improving the chance of recovery. The healthcare system need improvements to manage patients with non-alcoholic fatty liver disease and alcoholic fatty liver disease, as they have the potential to progress to cirrhosis. Both conditions involve the release of reactive oxygen species and damage-associated molecular patterns from cytokines, hepatic stellate cells, and hepatocyte autophagy, leading to prolonged inflammation. While various medications target fibrosis and liver damage, nanoparticle-based drug delivery systems offer additional promise by promoting faster liver regeneration. This review provides a comprehensive overview of the potential of nanoparticle systems as a future therapeutic approach for treating liver disorders.http://www.sciencedirect.com/science/article/pii/S2542568425000273Chronic liver diseases (CLDs)Reactive oxygen species (ROS)AntioxidantsNanoparticles |
| spellingShingle | Sathiyamoorthy Padmanaban Ji-Won Baek Sai Sahithya Chamarthy Saipriya Chandrasekaran Antony V Samrot Vijayakumar Gosu In-Kyu Park Kamalakannan Radhakrishnan Don-Kyu Kim Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights Liver Research Chronic liver diseases (CLDs) Reactive oxygen species (ROS) Antioxidants Nanoparticles |
| title | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights |
| title_full | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights |
| title_fullStr | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights |
| title_full_unstemmed | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights |
| title_short | Nanoparticle-based therapeutic strategies for chronic liver diseases: Advances and insights |
| title_sort | nanoparticle based therapeutic strategies for chronic liver diseases advances and insights |
| topic | Chronic liver diseases (CLDs) Reactive oxygen species (ROS) Antioxidants Nanoparticles |
| url | http://www.sciencedirect.com/science/article/pii/S2542568425000273 |
| work_keys_str_mv | AT sathiyamoorthypadmanaban nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT jiwonbaek nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT saisahithyachamarthy nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT saipriyachandrasekaran nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT antonyvsamrot nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT vijayakumargosu nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT inkyupark nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT kamalakannanradhakrishnan nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights AT donkyukim nanoparticlebasedtherapeuticstrategiesforchronicliverdiseasesadvancesandinsights |